C-7 Progesterone Analogues and MDR1 in Breast Cancer
Abstract
We have generated novel analogs of progesterone (PgA) as potent inhibitors of the MDRl multidrug resistant phenotype in breast cancer. The objectives of this Research Project include the optimization of the PgA's MDRl-reversing activity through the generation of additional compounds, using an analog design approach, the definition of these compounds' in vivo efficacy, and of their mechanism of action. In the course of the fourth year of the Project, we have: 1. tested the in vivo MDR-reversing activity of PgA4, the most potent among our initial progesterone analogs; 2. designed and synthesized additional progesterone analogs and evaluated their structure-activity relationships; 3. related the in vitro activity of some of the analogs to their in vitro toxicity.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2000
- Accession Number
- ADA406203
Entities
People
- Robert R. Clark
Organizations
- Georgetown University